BioVersys Expands Collaboration with GSK

BioVersys Expands Collaboration with GSK

By, Admin 9 May 2024

BioVersys Expands Collaboration with GSK and Boosts Series C Funding by CHF 12.3 Million

Overview

BioVersys AG, a clinical-stage biopharmaceutical company, and GSK plc (LSE/NYSE: GSK), a global biopharma leader, have announced an expansion of their strategic collaboration to accelerate the clinical development of alpibectir (BVL-GSK098) for tuberculosis (TB) treatment.

Alpibectir

  • Alpibectir, a novel small molecule developed through a successful public-private partnership involving GSK, Pasteur Institute Lille, and the University of Lille, is currently undergoing evaluation in a Phase 2a proof-of-concept study in pulmonary TB patients in South Africa. 
  • This compound, in combination with ethionamide (Eto), introduces a fresh approach to overcoming resistance and enhancing the effectiveness of existing antibiotics.

Extension in Collaboration

  • The collaboration between GSK and BioVersys will extend beyond the current Phase 2a study to develop alpibectir for both pulmonary TB and TB meningitis programs, aiming to make the treatment available to patients expeditiously.
  • Investment:- In addition to their collaboration, GSK will make an equity investment in BioVersys’ latest funding round, enhancing the Series C financing by CHF 12.3 million, totaling proceeds of CHF 44.9 million for the Series C round to date. These funds will support the clinical development of BioVersys’ portfolio, including BV100, a potential breakthrough antibiotic targeting Acinetobacter baumannii.

BioVersys on The Collab

  • • BioVersys, expressed enthusiasm about the expanded collaboration with GSK and the progress in alpibectir's development. 
  • • He emphasized the urgency in addressing TB, a global health threat with inadequate treatment options.

GSK on Potential of Alpibectir

GSK, highlighted the commitment to combatting TB and the potential of alpibectir to diversify treatment options. He emphasized the importance of partnerships in addressing global health challenges effectively.

About TB

  • TB, caused by Mycobacterium tuberculosis, remains a significant global health concern, with millions of new cases and deaths annually, and a rising incidence of drug-resistant strains. 
  • The collaboration between BioVersys and GSK represents a concerted effort to address this pressing public health issue.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!